HealthMore in Health→
Phase 1 Trial Shows Intracranial CAR-T Therapy for Recurrent Glioblastoma Is Safe and Feasible
Key Takeaways
- Phase 1 dose-escalation trial of intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma.
- Study published in Nature Medicine, demonstrating safety and feasibility.
- No dose-limiting toxicities; manageable adverse events.
- Preliminary signs of antitumor activity observed.
DE
DT Editorial Team··via nature.com
